Xenon Pharmaceuticals (XENE) Outlines 2022 Key Milestones

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. HUBS
2. EXPE
3. ARM
4. FIS
5. BROS
6. QCOM
7. DDOG
8. EW
9. ZG
10. W

Go back to Xenon Pharmaceuticals (XENE) Outlines 2022 Key Milestones

Xenon Pharmaceuticals (XENE) Collaboration with Neurocrine (NBIX) Biosciences Achieves $15M Regulatory Milestone

January 12, 2022 8:04 AM EST

Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neurology-focused biopharmaceutical company, today announced that its collaboration to develop treatments for epilepsy with Neurocrine Biosciences, Inc. (Nasdaq: NBIX) achieved a regulatory milestone, which has triggered an aggregate payment of $15.0 million to Xenon. The U.S. Food and Drug Administration (FDA) accepted Neurocrines protocol amendment that expands the study population to include subjects aged between 2 and 11 years in the ongoing Phase 2 randomized, double-blind, placebo-controlled study to... More